Back

Intermittent levosimendan in advanced palliative heart failure improves quality of life and reduces heart failure decompensations: a single center-experience

19 May 2025 (15:51 - 17:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pharmacotherapy (1) Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Jeni Quintal

Hospital Center of Setubal, Setubal (Portugal)

5 More presentations in this session

Presentation thumbnail
Clinical and safety outcomes of a pharmacist-led medication therapy management clinic (MTM) for heart failure patients in a tertiary hospital in Singapore
Doctor W. Lin (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Guideline-directed medical therapy optimization among multi-ethnic groups of heart failure with reduced ejection fraction patients
Ms C. Chua (Kuching, MY)
Abstract Slides Video
Presentation thumbnail
Trends in angiotensin receptor/neprilysin inhibitor (ARNI) prescribing across multi-Centre, multi-ethnic heart failure population
Ms C. Chua (Kuching, MY)
Abstract Slides Video
Presentation thumbnail
Levosimendan in outpatients with Advanced heart failure and severe KidnEy disease: the out-LAKE registry
Doctor G. Uccello (Lecco, IT)
Abstract Slides Video
Presentation thumbnail
Trend of echocardiographic parameters, ventricular-arterial coupling, and biomarkers in advanced heart failure patients undergoing intermittent home-based levosimendan infusion
Doctor R. Pugliese (Brindisi, IT)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - pharmacotherapy (1)

The Event

Event poster

Heart Failure 2025

19 May 2025 15:51 CET
You may be interested in
thumbnail
Congress Presentation
The role of intermittent levosimendan infusions in patients with advanced heart failure: is it enough?
thumbnail
Congress Presentation
Single centre 3-year experience in intermittent levosimendan infusion
thumbnail
Congress Presentation
Intermittent levosimendan therapy and survival outcomes in advanced heart failure: insights from a real-world single-centre study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources